ストックスクリーナーアプリを入手
0.5827
3.81%
0.0214
前日終値:
$0.5613
開ける：
$0.5612
24時間の取引高:
71,831
Relative Volume:
0.12
時価総額：
$16.00M
収益：
$5.61M
当期純損益:
$-55.45M
株価収益率:
-0.2267
EPS:
-2.5703
ネットキャッシュフロー:
$-42.35M
1週間 パフォーマンス:
+1.41%
1か月 パフォーマンス:
+5.39%
6か月 パフォーマンス:
-34.36%
1年 パフォーマンス:
-64.25%
1日の値動き範囲:
$0.5612
$0.61
1週間の範囲:
$0.55
$0.62
52週間の値動き範囲:
$0.476
$2.19
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.5827 | 16.00M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Enterprise value to revenue forward of Citius Pharmaceuticals Inc – LS:A40MD0 - TradingView
Citius Pharmaceuticals updates pipeline as investors track CTXR stock - ad-hoc-news.de
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why - Insider Financial
A40MD0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
47N0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (FWB:47N0) - TradingView
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR) - TradingView
CTXR Forecast — Price Target — Prediction for 2027 - TradingView
Citius Pharmaceuticals updates I/ ONTAK launch progress, shares trade on Nasdaq - AD HOC NEWS
Citius Pharmaceuticals Inc (CTXR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - BioSpace
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
LYMPHIR combo study finds 24% response, disease control up to 35 months - Stock Titan
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - simplywall.st
Citius Pharmaceuticals (CTXR) Edges Higher as Trading Volume Remains SubduedETF Outflow Streak - dars.gov.et
CTXRCitius Pharmaceuticals Inc Stock Price and Quote - Finviz
CTORCitius Oncology Inc Stock Price and Quote - Finviz
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - marketscreener.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
5 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):